OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Meeting Abstract

Industry Collaboration

cited authors

  • Aghajanian, C., Finkler, N. J., Rutherford, T., Smith, D. A., Yi, J., Parmar, H., Nycum, L. R., Sovak, M. A.

Publication Date

  • May 20, 2011

webpage

published in

category

volume

  • 29

issue

  • 15

WoS Citations

  • 0

WoS References

  • 0